---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-056664"
form_type: "8-K"
ticker: "AEON"
cik: "0001837607"
company_name: "AEON Biopharma, Inc."
filed_at: "2024-05-03T23:59:59+00:00"
generated_at: "2026-06-02T23:18:44.908695+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# AEON Biopharma Phase 2 trial of ABP-450 for chronic migraine fails primary endpoint

## Summary
- Primary endpoint: mean reduction in monthly migraine days (MMD) at weeks 13-24 was 8.5 (150U), 7.7 (195U), 8.4 (placebo); p=0.9132 and 0.3611.
- Trial did not achieve statistical significance for primary or any secondary endpoints; placebo response was unexpectedly higher than historical studies.
- Company immediately commencing cash preservation measures and reviewing all strategic options for ABP-450 development.

## SEC filing metadata
- accession: 0001104659-24-056664
- form_type: 8-K
- ticker: AEON
- cik: 0001837607
- company_name: AEON Biopharma, Inc.
- filed_at: 2024-05-03T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1837607/000110465924056664/0001104659-24-056664-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1837607/000110465924056664/tm2413422d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-056664
- JSON: https://secwatch.observer/filing/0001104659-24-056664.json
- Plain text: https://secwatch.observer/filing/0001104659-24-056664.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.